These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 31702636)

  • 21. Alzheimer Disease and Mild Cognitive Impairment: Integrated Pulsed Arterial Spin-Labeling MRI and
    Riederer I; Bohn KP; Preibisch C; Wiedemann E; Zimmer C; Alexopoulos P; Förster S
    Radiology; 2018 Jul; 288(1):198-206. PubMed ID: 29762090
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multimodal and Multiscale Deep Neural Networks for the Early Diagnosis of Alzheimer's Disease using structural MR and FDG-PET images.
    Lu D; Popuri K; Ding GW; Balachandar R; Beg MF;
    Sci Rep; 2018 Apr; 8(1):5697. PubMed ID: 29632364
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Amyloid load but not regional glucose metabolism predicts conversion to Alzheimer's dementia in a memory clinic population.
    Frings L; Hellwig S; Bormann T; Spehl TS; Buchert R; Meyer PT
    Eur J Nucl Med Mol Imaging; 2018 Jul; 45(8):1442-1448. PubMed ID: 29546632
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diagnostic role of 11C-Pittsburgh compound B retention patterns and glucose metabolism by fluorine-18-fluorodeoxyglucose PET/CT in amnestic and nonamnestic mild cognitive impairment patients.
    Jiménez-Bonilla JF; Banzo I; De Arcocha-Torres M; Quirce R; Martínez-Rodríguez I; Lavado-Pérez C; Bravo-Ferrer Z; Rodríguez-Rodríguez E; Sánchez-Juan P; Carril JM
    Nucl Med Commun; 2016 Nov; 37(11):1189-96. PubMed ID: 27341411
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discriminative Power of Arterial Spin Labeling Magnetic Resonance Imaging and 18F-Fluorodeoxyglucose Positron Emission Tomography Changes for Amyloid-β-Positive Subjects in the Alzheimer's Disease Continuum.
    Tosun D; Schuff N; Jagust W; Weiner MW;
    Neurodegener Dis; 2016; 16(1-2):87-94. PubMed ID: 26560336
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of dynamic susceptibility contrast enhanced MR and FDG-PET brain studies in patients with Alzheimer's disease and amnestic mild cognitive impairment.
    Wabik A; Trypka E; Bladowska J; Statkiewicz M; Sąsiadek M; Zimny A
    J Transl Med; 2022 Jun; 20(1):259. PubMed ID: 35672750
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Simultaneous FDG-PET/MRI detects hippocampal subfield metabolic differences in AD/MCI.
    Carlson ML; DiGiacomo PS; Fan AP; Goubran M; Khalighi MM; Chao SZ; Vasanawala M; Wintermark M; Mormino E; Zaharchuk G; James ML; Zeineh MM
    Sci Rep; 2020 Jul; 10(1):12064. PubMed ID: 32694602
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Joint Assessment of Quantitative 18F-Florbetapir and 18F-FDG Regional Uptake Using Baseline Data from the ADNI.
    Ben Bouallègue F; Mariano-Goulart D; Payoux P;
    J Alzheimers Dis; 2018; 62(1):399-408. PubMed ID: 29439345
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of imaging modalities, brain atlases and feature selection on prediction of Alzheimer's disease.
    Ota K; Oishi N; Ito K; Fukuyama H; ;
    J Neurosci Methods; 2015 Dec; 256():168-83. PubMed ID: 26318777
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnostic manifestations of total hemispheric glucose metabolism ratio in neuronal network diaschisis: diagnostic implications in Alzheimer's disease and mild cognitive impairment.
    Segtnan EA; Majdi A; Constantinescu C; Grupe P; Gerke O; Dali HÍ; Strøm OE; Holm J; Alavi A; Sadigh-Eteghad S; Wermuth L; Hildebrandt MG; Gjedde A; Høilund-Carlsen PF
    Eur J Nucl Med Mol Imaging; 2019 May; 46(5):1164-1174. PubMed ID: 30637500
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluating the association between brain atrophy, hypometabolism, and cognitive decline in Alzheimer's disease: a PET/MRI study.
    Chen Y; Wang J; Cui C; Su Y; Jing D; Wu L; Liang P; Liang Z
    Aging (Albany NY); 2021 Feb; 13(5):7228-7246. PubMed ID: 33640881
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The impact of atlas-based MR attenuation correction on the diagnosis of FDG-PET/MR for Alzheimer's diseases- A simulation study combining multi-center data and ADNI-data.
    Sekine T; Buck A; Delso G; Kemp B; Ter Voert EEGW; Huellner M; Veit-Haibach P; Kaushik S; Wiesinger F; Warnock G;
    PLoS One; 2020; 15(6):e0233886. PubMed ID: 32492074
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of ApoE ε4 on longitudinal brain region-specific glucose metabolism in patients with mild cognitive impairment: a FDG-PET study.
    Paranjpe MD; Chen X; Liu M; Paranjpe I; Leal JP; Wang R; Pomper MG; Wong DF; Benzinger TLS; Zhou Y;
    Neuroimage Clin; 2019; 22():101795. PubMed ID: 30991617
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Simultaneous resting-state FDG-PET/fMRI in Alzheimer Disease: Relationship between glucose metabolism and intrinsic activity.
    Marchitelli R; Aiello M; Cachia A; Quarantelli M; Cavaliere C; Postiglione A; Tedeschi G; Montella P; Milan G; Salvatore M; Salvatore E; Baron JC; Pappatà S
    Neuroimage; 2018 Aug; 176():246-258. PubMed ID: 29709628
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Direct comparison of fluorodeoxyglucose positron emission tomography and arterial spin labeling magnetic resonance imaging in Alzheimer's disease.
    Musiek ES; Chen Y; Korczykowski M; Saboury B; Martinez PM; Reddin JS; Alavi A; Kimberg DY; Wolk DA; Julin P; Newberg AB; Arnold SE; Detre JA
    Alzheimers Dement; 2012 Jan; 8(1):51-9. PubMed ID: 22018493
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Potential Clinical Value of Multiparametric PET in the Prediction of Alzheimer's Disease Progression.
    Chen X; Zhou Y; Wang R; Cao H; Reid S; Gao R; Han D;
    PLoS One; 2016; 11(5):e0154406. PubMed ID: 27183116
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Cross-Validation of FDG- and Amyloid-PET Biomarkers in Mild Cognitive Impairment for the Risk Prediction to Dementia due to Alzheimer's Disease in a Clinical Setting.
    Iaccarino L; Chiotis K; Alongi P; Almkvist O; Wall A; Cerami C; Bettinardi V; Gianolli L; Nordberg A; Perani D
    J Alzheimers Dis; 2017; 59(2):603-614. PubMed ID: 28671117
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Patients with Amyloid-Negative Mild Cognitive Impairment have Cortical Hypometabolism but the Hippocampus is Preserved.
    Hanseeuw B; Dricot L; Lhommel R; Quenon L; Ivanoiu A
    J Alzheimers Dis; 2016 May; 53(2):651-60. PubMed ID: 27232217
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Age- and Brain Region-Specific Changes of Glucose Metabolic Disorder, Learning, and Memory Dysfunction in Early Alzheimer's Disease Assessed in APP/PS1 Transgenic Mice Using
    Li XY; Men WW; Zhu H; Lei JF; Zuo FX; Wang ZJ; Zhu ZH; Bao XJ; Wang RZ
    Int J Mol Sci; 2016 Oct; 17(10):. PubMed ID: 27763550
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relative capability of MR imaging and FDG PET to depict changes associated with prodromal and early Alzheimer disease.
    Karow DS; McEvoy LK; Fennema-Notestine C; Hagler DJ; Jennings RG; Brewer JB; Hoh CK; Dale AM;
    Radiology; 2010 Sep; 256(3):932-42. PubMed ID: 20720076
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.